SCHEMBL1546945

SCHEMBL1546945

CCCN1CCC(c2cccc(NS(=O)(=O)c3ccc(C(C)C)cc3)c2)C1

nearest known ligand 0.57

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SLC2A1 P11166 1/20 0.55
DRD2 P14416 10/20 0.50
DRD3 P35462 8/20 0.50
SIGMAR1 Q99720 1/20 0.50
DRD1 P21728 3/20 0.46
DRD4 P21917 3/20 0.46
DRD5 P21918 3/20 0.46
ALDH1A1 P00352 1/20 0.45
HTT P42858 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
TRIM24 O15164 1/20 0.44
BRD1 O95696 1/20 0.44
BRPF1 P55201 1/20 0.44
ACHE P22303 1/20 0.44
KCNH2 Q12809 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1752116 0.99 SLC2A1 (0.54) SLC2A1DRD2DRD3SIGMAR1DRD1
SCHEMBL1561499 0.94 DRD3 (0.59) SLC2A1DRD2DRD3SIGMAR1DRD1
SCHEMBL1546261 0.88 SLC2A1 (0.53) SLC2A1DRD2DRD3ALDH1A1HTT
SCHEMBL5574178 0.88 DRD2 (0.52) SLC2A1DRD2DRD3DRD1DRD4
SCHEMBL1545864 0.88 DRD2 (0.52) SLC2A1DRD2DRD3DRD1DRD4
SCHEMBL1545866 0.88 DRD2 (0.52) SLC2A1DRD2DRD3DRD1DRD4
Hydrochloric Acid SCHEMBL1752315 0.87 SLC2A1 (0.52) SLC2A1DRD2DRD3ALDH1A1HTT
Hydrochloric Acid SCHEMBL1545751 0.87 DRD2 (0.51) SLC2A1DRD2DRD3ALDH1A1SMN1; SMN2
Hydrochloric Acid SCHEMBL1546697 0.87 DRD2 (0.51) SLC2A1DRD2DRD3ALDH1A1SMN1; SMN2
Hydrochloric Acid SCHEMBL1545749 0.87 DRD2 (0.51) SLC2A1DRD2DRD3ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2311802-A1 Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor Abbott GmbH & Co. KG (DE) 2011-04-20 EP disclosed
EP-2311803-A1 Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor Abbott GmbH & Co. KG (DE) 2011-04-20 EP disclosed
EP-1814849-B1 HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR ABBOTT GMBH & CO KG (DE) 2011-04-06 EP disclosed
EP-1814849-A1 HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR Abbott GmbH & Co. KG (DE) 2007-08-08 EP disclosed
WO-2006040182-A1 HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR ABBOTT GMBH & CO. KG (DE) 2006-04-20 WO disclosed